Skip to main navigation Skip to search Skip to main content

Clinical presentation of stage IIIA (N2) non-small cell lung cancer: Role of multimodality therapy cancer

  • University of Pennsylvania

Research output: Contribution to journal › Article › peer-review

Abstract

Neoadjuvant chemotherapy before surgical resection of locally advanced non-small cell lung cancer (NSCLC) has been shown to improve survival compared with surgery alone in several randomized clinical trials. A case report is presented describing the use of paclitaxel and carboplatin in a multimodality regimen for a patient with stage IIIA N2 NSCLC. Studies are ongoing to determine the optimal type and timing of chemotherapy.

Original languageEnglish
Pages (from-to)497S-499S
JournalChest
Volume116
Issue number6 SUPPL.
DOIs
StatePublished - 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Multimodality therapy
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer
  • Stage IIIA N2 disease
  • Surgery

Fingerprint

Dive into the research topics of 'Clinical presentation of stage IIIA (N2) non-small cell lung cancer: Role of multimodality therapy cancer'. Together they form a unique fingerprint.

Cite this